Beroctocog alfa
- Generic Name
- Beroctocog alfa
- Brand Names
- Alphanate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9001-27-8
- Unique Ingredient Identifier
- 17RNR4H479
- Indication
Beroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in adult and pediatric patients with von Willebrand Disease in who desmopression is either ineffective or contraindicated. It is not indicated for patients with severe (i.e. type 3) von Willebrand Disease whom are undergoing major surgery.
- Associated Conditions
- Bleeding
- Associated Therapies
- Perioperative management therapy
Treatment options for hemophilia A
Hemophilia A, caused by F8 gene mutation, leads to factor VIII deficiency, impairing blood clotting. Treatment includes factor VIII replacement, immunotherapies, and gene therapy, aiming to manage bleeding and prevent inhibitor development.
U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults ...
FDA approves HYMPAVZI™ for routine prophylaxis in hemophilia A or B without inhibitors, offering a once-weekly subcutaneous treatment with a manageable safety profile and minimal preparation.
U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults
U.S. FDA approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for hemophilia A or B without inhibitors, based on Phase 3 study results showing substantial bleed reduction. HYMPAVZI is the first once-weekly subcutaneous prophylactic treatment for hemophilia B and the first to use a pre-filled pen or syringe for hemophilia A or B.
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents
Pfizer's HYMPAVZI, approved by the FDA, is the first once-weekly subcutaneous treatment for hemophilia A or B without inhibitors in patients 12 and older, based on Phase 3 study results showing significant bleed reduction. It's administered via pre-filled pen or syringe, addressing a global need affecting over 800,000 people.
FDA Approves Marstacimab-hncq (Hympavzi) for Hemophilia A or B Without Inhibitors
The FDA approved Pfizer’s marstacimab-hncq (Hympavzi) for hemophilia A/B without inhibitors, reducing annualized bleeding rates by 35% and 92% compared to routine prophylaxis and on-demand treatment. The drug, administered via a pre-filled auto-injector pen, marks a significant advancement in hemophilia treatment.
FDA Approves Hympavzi (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
FDA approves Hympavzi (marstacimab-hncq) for hemophilia A or B without inhibitors, offering a once-weekly subcutaneous treatment option.
Infected blood scandal: Children were used as 'guinea pigs' in clinical trials
In the 1970s-80s, UK children with blood disorders were used in unsafe clinical trials with infected blood products, leading to hepatitis C and HIV infections. Many died, with families often unaware. A public inquiry is ongoing, revealing doctors prioritized research over patient safety, using high-risk imported blood products.
CHOP-led Study Shows Novel Gene Therapy for Hemophilia A Leads to Sustained Expression of Clotting Factor and Reduced Bleeding Events
A novel gene therapy for hemophilia A, SPK-8011, demonstrated sustained FVIII expression, reducing bleeding episodes significantly. The phase 1/2 trial, led by CHOP, showed stable coagulation factor VIII levels in patients, with a 91.5% reduction in bleeding. Funded by Spark Therapeutics, the study supports liver-directed AAV gene therapy for long-term hemophilia A treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath